Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 9/20 | 0.60 |
| ▸ | CDK8 | P49336 | 4/20 | 0.60 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.54 |
| ▸ | SGK1 | O00141 | 3/20 | 0.52 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113953 | 0.86 | DYRK1A (0.70) | AXLRIPK1SGK1CAMKK2DYRK1A | |
| SCHEMBL29337209 | 0.79 | RIPK1 (0.77) | AXLCDK8TNIKGSK3BRIPK1 | |
| SCHEMBL30987950 | 0.79 | RIPK1 (0.77) | AXLCDK8TNIKGSK3BRIPK1 | |
| SCHEMBL23166582 | 0.76 | DYRK1A (0.39) | GSK3BDYRK1ADYRK1B | |
| SCHEMBL7114099 | 0.76 | DYRK1A (0.48) | CDK8GSK3BDYRK1ADYRK1BIGF1R | |
| SCHEMBL15155057 | 0.76 | JAK2 (0.48) | DYRK1ADYRK1B | |
| SCHEMBL15154912 | 0.76 | SMN1; SMN2 (0.44) | DYRK1ADYRK1B | |
| SCHEMBL7112799 | 0.76 | KIT (0.53) | DYRK1ADYRK1B | |
| SCHEMBL29337212 | 0.76 | RIPK1 (0.60) | AXLCDK8TNIKRIPK1SGK1 | |
| SCHEMBL30987941 | 0.76 | RIPK1 (0.60) | AXLCDK8TNIKRIPK1SGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003028724-A1 | CHK1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |